GlassScriptPhysician profile
Roy R Liu
NPI 1346582996
$2,148.65
in general payments reported to CMS, 2019-2025
14 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.14 · 2020: $1,061 · 2021: $281 · 2022: $81.66 · 2023: $213 · 2024: $198 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,003.84 | 2020 | |
| Biotronik Nro, INC. | $257.60 | 2023-2025 | Prospera, Biotronik |
| Boston Scientific Corporation | $188.63 | 2019-2022 | |
| Nevro Corp. | $185.45 | 2020-2023 | Senza |
| Si-Bone, INC. | $129.02 | 2021 | |
| Alphatec Spine, INC | $106.35 | 2024 | Identiti |
| Curonix LLC | $91.67 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $53.00 | 2021-2025 | Xtampza |
| Abbott Laboratories | $37.43 | 2021 | |
| Medtronic, INC. | $24.37 | 2023 | Closurefast |
| Pacira Pharmaceuticals Incorporated | $21.77 | 2022 | |
| Forte Bio-Pharma LLC | $17.70 | 2025 | Prolate, Nalocet, Tanlor |
| Nalu Medical, INC. | $16.60 | 2023 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.22 | 2023 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.